Trevena (TRVN) seeks to submit its opioid painkiller oliceridine for FDA marketing approval in the fourth quarter. Oliceridine intends to provide post-surgery intravenous pain relief comparable with standard morphine, while reducing common side effects that include nausea, vomiting and depressed breathing. Although these side effects are known for increasing hospital stays and costs, if approved, the pain killer will be significantly more expensive than morphine. Will hospitals be able to justify the cost?
Despite the president's promise of no stimulus until after Nov. 3, there are no signs yet that this is the sort of correlated selling that leads to a deep correction.
Breaking down an approach to the long side of this biotech stock.
Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation.
If you have questions, please contact us here.
Email
Email sent
Thank you, your email to has been sent successfully.
